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Abstract
Background:  The population pharmacokinetics of artesunate (AS) and its active metabolite
dihydroartemisinin (DHA) were studied in healthy subjects receiving single- or multiple-dosing of
AS orally either in combination with pyronaridine (PYR) or as a monotherapy with or without food.
Methods: Data from 118 concentration-time profiles arising from 91 healthy Korean subjects
were pooled from four Phase I clinical studies. Subjects received 2-5 mg/kg of single- and multiple-
dosing of oral AS either in combination with PYR or as a monotherapy with or without food.
Plasma AS and DHA were measured simultaneously using a validated liquid chromatography- mass
spectrometric method with a lower limit of quantification of 1 ng/mL for both AS and DHA.
Nonlinear mixed-effect modelling was used to obtain the pharmacokinetic and variability (inter-
individual and residual variability) parameter estimates.
Results: A novel parent-metabolite pharmacokinetic model consisting of a dosing compartment, a
central compartment for AS, a central compartment and a peripheral compartment for DHA was
developed. AS and DHA data were modelled simultaneously assuming stoichiometric conversion
to DHA. AS was rapidly absorbed with a population estimate of absorption rate constant (Ka) of
3.85 h-1. The population estimates of apparent clearance (CL/F) and volume of distribution (V2/F)
for AS were 1190 L/h with 36.2% inter-individual variability (IIV) and 1210 L with 57.4% IIV,
respectively. For DHA, the population estimates of apparent clearance (CLM/F) and central volume
of distribution (V3/F) were 93.7 L/h with 28% IIV and 97.1 L with 30% IIV, respectively. The
population estimates of apparent inter-compartmental clearance (Q/F) and peripheral volume of
distribution (V4/F) for DHA were 5.74 L/h and 18.5 L, respectively. Intake of high-fat and high-
caloric meal prior to the drug administration resulted in 84% reduction in Ka. Body weight
impacted CLM/F, such that a unit change in weight resulted in 1.9-unit change in CLM/F in the same
direction.
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Conclusions:  A novel simultaneous parent-metabolite pharmacokinetic model with good
predictive power was developed to study the population pharmacokinetics of AS and DHA in
healthy subjects following single- and multiple-dosing of AS with or without the presence of food.
Food intake and weight were significant covariates for Ka and CLM/F, respectively.
Background
Malaria is one of the deadliest infectious diseases in the
world, causing nearly a million deaths among more than
three billion people who were at risk in 2006 [1]. Unfor-
tunately, given the high burden of the disease, the number
of available anti-malarial drugs is relatively small. On top
of that, the emergence of resistance to the most affordable
anti-malarial drugs has seriously undermined the global
effort to control malaria. As the result of chloroquine and
sulphadoxine-pyrimethamine resistance, millions of lives
that could otherwise be saved were sacrificed over the past
30 years [2]. Artemisinin-based combination therapy
(ACT) is now being widely used as the first-line treatment
for Plasmodium falciparum malaria throughout the world.
Artemisinin (ARN) and its derivatives, dihydroartemisi-
nin (DHA), artesunate (AS), artemether and arteether are
fast acting anti-malarial drugs producing the most rapid
reduction in parasitaemia [3]. These agents also have
gametocytocidal activity, which contributes to the reduc-
tion in the disease transmission [4,5]. Among the availa-
ble derivatives, AS has the most appealing
physicochemical and pharmacological properties. It is
more water soluble, thermally and chemically more sta-
ble, and rapidly converted in vivo to its active metabolite
DHA, which is responsible for most of the anti-malarial
activity [6,7].
Pyronaridine (PYR) is a Mannich-base derivative anti-
malarial that has been shown to be efficacious against
erythrocytic stages of P. falciparum using in vitro models
[8-10]. Clinical studies have also indicated that PYR is safe
and efficacious against P. falciparum even in area with
chloroquine-resistant strains [11-13]. Pyronaridine tetra-
phosphate plus artesunate (PA) is under development as
a 3:1 fixed ratio combination for the treatment against P.
falciparum and P. vivax malaria.
Population pharmacokinetics of AS and/or DHA follow-
ing the administration of AS have been previously
described in malaria patients. Karunajeewa and col-
leagues investigated the disposition of AS and DHA in 47
children from Papua New Guinea with uncomplicated
malaria after the administration of AS suppositories [14].
The population pharmacokinetics of DHA were also
assessed in 164 patients with moderately severe falci-
parum malaria following intra-rectal dosing of AS, in 24
pregnant women and in 70 African children with acute
uncomplicated falciparum malaria after the administra-
tion of oral AS [15-17]. However, parent AS data were not
modelled in these two studies, mainly because there were
too few data points available for AS.
To date, no population pharmacokinetics analysis of AS
and DHA has been published in healthy subjects receiving
oral AS dosing. Such analysis will provide a means of
comparing the pharmacokinetics of AS and DHA in
malaria patients and healthy subjects and, therefore,
expand the understanding in the effect of the disease state
on the pharmacokinetics of AS and DHA. The aims of this
analysis are to develop a population pharmacokinetic
model of AS and DHA in healthy subjects following oral
administration of PA combination or AS alone and to
identify covariates that are important determinants of the
variability seen in pharmacokinetic parameters of AS and
DHA.
Methods
Subjects and study designs
Data used in performing this analysis were pooled from a
four-part Phase I clinical trial (Protocol number SP-C-
001-03). The trial was conducted at the Clinical Trial
Center of Seoul National University, Seoul, South Korea,
in accordance with the Guidelines of Good Clinical Prac-
tice and Declaration of Helsinki. Ethical approval was
obtained from Institutional Review Board of Seoul
National University. Written informed consent was
obtained from each subject prior to the studies. All sub-
jects were healthy Korean men and women evaluated by a
physician at screening (Day -21 to -2) based on physical
examination, vital signs, electrocardiogram, medical his-
tory and laboratory evaluations. All study drugs and pla-
cebos were provided by Shin Poong Pharmaceuticals
(Seoul, Korea) and were identical in appearance to main-
tain blinding.
The first part was designed as a single oral ascending dose,
randomized, double-blind, placebo-controlled, staggered
and parallel group study to evaluate the pharmacokinet-
ics, safety and tolerability of PA following single oral
administration of PA at following doses: 6+2 mg/kg, 9+3
mg/kg, 12+4 mg/kg or 15+5 mg/kg. Nine subjects were
recruited for each dose level, and randomized to receiving
either PA treatment or placebo in 7:2 ratio.
The second part was conducted to evaluate the potential
of drug interaction between PYR and AS when used as a
combination in 3:1 ratio. It was a two-cohort parallel,Malaria Journal 2009, 8:304 http://www.malariajournal.com/content/8/1/304
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two-period randomized, blinded, crossover study of a sin-
gle oral dose of PA 12+4 mg/kg versus each of the individ-
ual drug at the same dose plus placebo of the other drug.
20 subjects were enrolled into this study, and randomly
assigned into either cohort 1 or cohort 2 in equal num-
bers. In cohort 1, five subjects received PYR alone in
period 1 followed by PA combination in period 2, while
another five received the treatments in reverse order. In
cohort 2, five subjects received AS alone in period 1 fol-
lowed by PA combination in period 2, while another five
received the treatments in reverse order. There was a 21-
day washout period between the two periods.
The third study was a two-period, randomized and cross-
over study to investigate the effect of food on the pharma-
cokinetics of PA. 20 subjects were enrolled into the study
and randomly allocated to each of the fasted or the fed
arm in equal numbers. After an overnight fast of at least
10 hours, the subjects in the fasted arm received PA 12+4
mg/kg with 240 mL of water and remained fasted for at
least 4 hours post-dose while the subjects in the fed arm
ingested a high-fat and high-caloric test meal 30 minutes
prior to the treatment. After a washout period of 21 days,
the subjects returned for the crossover treatment. Water
was permitted as desired, except for one hour before and
after drug administration, and a standard meal was sched-
uled at the same time in each period of the study for each
subject.
The purpose of the last part of trial was to evaluate the
pharmacokinetics, safety and tolerability of PA following
multiple oral dosing of PA at following doses: 6+2 mg/kg,
9+3 mg/kg, 12+4 mg/kg or 15+5 mg/kg once daily for
three consecutive days. The study design was otherwise
similar to the design of the first study. Eight subjects were
recruited for each dose level, and randomized to receiving
either PA treatment or placebo in 6:2 ratio.
Sample collection and storage
For the first three studies, venous blood samples for the
determination of AS and DHA pharmacokinetics were col-
lected prior to dosing and at 0.33, 0.67, 1.33, 1.67, 2, 2.5,
3, 4, 5, 8 and 12 hours post-dose. For the multiple-dosing
study, the samples were taken prior to the dosing of each
dose and at 0.33, 0.67, 1, 1.33, 1.67, 2, 2.5, 3, 4, 5, 8 and
12 hours after the third dose. Blood samples were col-
lected into pre-chilled sampling tubes containing potas-
sium oxalate/sodium fluoride (BD Vacutainer systems,
Franklin Lakes, NJ) and placed on wet ice before centrifu-
gation within five minutes of collection. Immediately
after centrifugation, plasma was removed and transferred
into two approximately equal volume aliquots in screw
cap Nalgene cryovials and then frozen immediately at or
below -80°C until analysis.
Analytical method
Plasma concentration of AS and DHA were determined
using a validated liquid chromatography-mass spectro-
metric method described by Naik et al [18]. All samples
were assayed in the same laboratory. The plasma samples
spiked with internal standard ARN was cleaned up using
solid phase extraction method. Analysis was performed
with a Shimadzu Model 2010 liquid chromatograph-mass
spectrometer (Shimadzu, Columbia, MD) in single ion
monitoring positive mode using atmospheric pressure
chemical ionization as an interface. The lower limit of
quantification for AS and DHA using 0.5 mL of plasma
was 1 ng/mL. The coefficient of variation for intra-day and
inter-day precision ranged from 7% to 14% and 9% to
14% for AS, and 11% to 14.9% and 11% to 15% for DHA,
respectively.
Population pharmacokinetic analysis
Nonlinear mixed-effect model building was conducted
using NONMEM software version VI, level 2.0 (ICON
Development Solutions, Ellicott City, MD) [19], as imple-
mented on a Windows XP operating system (Microsoft
Corporation, WA, Seattle) with G95 Fortran compiler
(Free Software Foundation, Boston, MA). All models were
fitted using the first-order conditional estimation method.
NONMEM output was processed using PDx-Pop 3.10
(ICON Development Solutions, Ellicott City, MD) and
Xpose version 4.0 (Uppsala University, Uppsala, Sweden)
[20]. Graphical plots were produced using S-PLUS version
8.0 (Insightful Inc, Seattle, WA) and R 2.8.1 (Free Software
Foundation, Boston, MA).
Measurements below the lower limit of quantification of
the assay were excluded from the dataset. Since the molec-
ular weights of AS and DHA are quite different (384.4 for
AS and 284.9 for DHA), the concentrations were con-
verted to the equivalent values in nmols/L. AS dose was
also converted to the equivalent values in nmols. The con-
centrations were then natural log-transformed before the
analysis.
Model selection was guided by the plausibility of the esti-
mates, minimum objective function value (OFV), equal to
minus twice the log-likelihood function, Akaike Informa-
tion Criterion (AIC), equal to OFV plus two times the
number of parameters, condition number, defined as the
ratio of the largest Eigen value to the smallest Eigen value,
visual inspection of diagnostic plots and the precision of
parameter estimates.
In the initial stage of model building, one- and two-com-
partment pharmacokinetic models with first order
absorption and first order elimination were fitted to the
AS data to determine the best structural model for AS.
Once the best pharmacokinetic model for AS was deter-Malaria Journal 2009, 8:304 http://www.malariajournal.com/content/8/1/304
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mined, DHA data was modelled as a metabolite compart-
ment connected to the central compartment of AS. It was
assumed that conversion to DHA was the only significant
route of elimination for AS and that the conversion was
irreversible [21]. One- and two-compartment models
with first-order disposition were tested for DHA to
develop the best metabolite structural model. For the two-
compartment model, it was assumed that DHA was elim-
inated only from the central compartment. After the best
structural model was determined, all parameters were esti-
mated simultaneously using ADVAN 6 in NONMEM.
Inter-individual variability (IIV) of the pharmacokinetic
parameters was modelled assuming a log-normal distri-
bution, as follows:
where Pi is the estimated parameter value for individual i,
Ppop represents the typical population estimate for the
parameter and ηi is the deviation of Pi from Ppop. The η
random effects were assumed to be independent and sym-
metrically distributed with zero mean and variance ε2. A
diagonal covariance matrix was modelled, as the data did
not support the implementation of a full variance-covari-
ance matrix. The magnitude of IIV was expressed as coef-
ficient of variation (%CV), which was approximated by
the square root of the variance estimate.
Residual variability (RV) was modeled using an additive
model as shown below:
where Cij and Cpred, ij represent the jth observed and model
predicted AS or DHA concentrations, respectively, for
individual i and εij denotes the additive residual random
error for individual i and observation j. The ε random
effects were assumed to be independent and symmetri-
cally distributed with zero mean and variance σ2.
After the optimum model for AS and DHA was deter-
mined, covariate analysis was carried out to assess addi-
tional variables as possible determinants of the variability
seen in the pharmacokinetic estimates. Covariates exam-
ined include total body weight, age, gender, type of dosing
(single- or multiple-dosing), treatment (co-administra-
tion of PYR) and food intake (fasted or fed). A summary
of the covariates evaluated is shown in Table 1. Potential
covariates were initially identified using generalized addi-
tive modelling (GAM) as implemented in the Xpose soft-
ware. The potential covariates were then tested using
PP i pop i = iexp( ) h
ln ln CC ij pred,ij ij =+ e
Table 1: A summary of the study data, subject demographics and covariates included in the analysis.
Characteristic Single dose study Drug interaction 
study
Food effect study Multiple dose study Combined
No. of subjects 28 19 20 24 91
No. of 
concentration-time 
profiles
28 28 38 24 118
No. of 
observations
AS 206 207 324 179 916
DHA 316 314 449 273 1352
AS dose (mg/kg) 2, 3, 4 or 5 4 4 2, 3, 4 or 5 2, 3, 4 or 5
Sampling schedule Predose, 0.33, 0.67, 1, 
1.33, 1.67, 2, 2.5, 3, 4, 5, 
8 and 12 h postdose
Predose, 0.33, 0.67, 1, 
1.33, 1.67, 2, 2.5, 3, 4, 5, 
8 and 12 h postdose
Predose, 0.33, 0.67, 1, 
1.33, 1.67, 2, 2.5, 3, 4, 5, 
8 and 12 h postdose
Immediately prior to each 
dose and 0.33, 0.67, 1, 1.33, 
1.67, 2, 2.5, 3, 4, 5, 8 and 12 
h after the third dose
NA
Age (years) 24 (19-40) 23 (20-32) 21.5 (19-27) 23 (19-29) 23 (19-40)
Weight (kg) 62.5 (50.4-70) 60.9 (50.1-67.1) 59.9 (50.8-68.5) 62.2 (51.2-68.8) 61.5 (50.1-70)
Sex (number)
Female 9 10 10 9 38
Male 19 9 10 15 53
Type of dosing Single Single Single Multiple 
(once daily for 3 days)
NA
Food intake 
(number of 
profiles)
Fasted 28 28 19 24 99
Fed 0 0 19 0 19
AS, artesunate; DHA, dihydroartemisinin.
Continuous variables are given as median (range).Malaria Journal 2009, 8:304 http://www.malariajournal.com/content/8/1/304
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stepwise forward addition followed by stepwise backward
elimination procedure [22]. The influences of the covari-
ates were tested by adding a covariate to the model at a
time in the forward addition step, and then by removing
a covariate from the model at a time in the backward elim-
ination step. The changes in OFV between the 'full' and
the 'reduced' models were then calculated. The difference
in OFV between two nested models was approximated by
a χ2 distribution. An OFV change of 3.84 (corresponding
to a significance level of 5% at one degree of freedom) was
used as the cut-off to include a covariate in stepwise addi-
tion. When no more covariates could be included, the
stepwise backward elimination was carried out. For a cov-
ariate to remain in the model, a change in OFV of at least
10.83 (corresponding to a significance level of 0.1% at
one degree of freedom) was needed.
The relationship between continuous covariates and phar-
macokinetic parameters were evaluated using both linear
and power functions, with the covariates centered or
scaled at their median values:
where θ1 represents the parameter estimate P of an indi-
vidual with a body weight of 61.5 kg and θ2 is a factor
describing the correlation between body weight and the
parameter. The influences of binary covariates on the
parameter were modelled using a proportional relation-
ship, as follow:
where θ3 represents the parameter value in subjects receiv-
ing the test drug without food, and θ4 is the fractional
change in the parameter in subjects receiving the test drug
with food. FOOD variable was coded as 0 for the fasted
subjects and 1 for the subjects who received test drug with
food.
Model evaluation
The non-parametric bootstrap procedure was employed
to evaluate the precision of the parameter estimates and
the robustness of the final model. 500 bootstrap datasets
were generated by repeated random sampling with
replacement from the NONMEM input data file, and the
final NONMEM model was fitted to the bootstrap data-
sets. Bootstrap parameter estimates, standard errors and
95% confidence intervals were obtained and compared
with the parameter estimates from the original dataset.
Visual predictive check was also performed to evaluate the
predictive ability of the model. 500 virtual observations at
each sampling time point were simulated using the final
model and its parameter estimates. The observed data
were then plotted with the 5th, 50th and 95th percentiles
of the simulated data that was above the limit of quatifi-
cation. The percent of observations outside the 90% pre-
diction interval was also calculated. The condition
number of the final model was also calculated as a meas-
ure of the stability of the model.
Results
Demographic data
Data from 118 concentration-time profiles arising from
91 healthy Korean subjects were pooled from four clinical
studies. The subjects received single- or multiple-dosing of
2-5 mg/kg AS orally either in combination with PYR or as
a monotherapy with or without food. A total of nine and
18 subjects contributed two pharmacokinetic profiles
each in separate occasions for the drug-interaction and
food effect study, respectively. Since the elimination half-
lives for AS and DHA are very short and the elimination of
the drugs are deemed to have completed after the 21-day
washout period, the pharmacokinetic profiles arising
from the same subject in different occasions were treated
as independent profiles. 916 and 1,352 concentration
measurements for AS and DHA respectively were used in
the modelling. A summary of the study designs, subject
demographics and covariates is shown in Table 1.
Population pharmacokinetic model
A one-compartment model with first order absorption
and first order elimination best described the AS data.
When a two-compartment model was fitted to the AS
data, minimum OFV and AIC were reduced moderately
(11.897 and 3.897 unit, respectively). However, the visual
inspection of goodness-of-fit plots showed no improve-
ment in the fit. The precision of the estimates obtained
were also slightly worse. Consequently, the simpler one-
compartment model was used to fit the AS data.
The DHA data were then sequentially modelled using a
one-compartment model with linear elimination and also
a two-compartment model. The two-compartment model
fitted the DHA data better, leading to165.186 and
157.186 unit reduction in OFV and AIC respectively.
Goodness-of-fit plots also showed obvious improvement
in the overall fit.
The final model used to simultaneously model the AS and
DHA data consisted of a dosing compartment, a central
compartment for AS, a central compartment and a periph-
eral compartment for DHA, as shown in Figure 1. The
model was parameterized in terms of absorption rate con-
stant for AS (Ka), apparent clearance for AS (CL/F, where
P WT  for linear function =+ − qq 12 61 5 i(. )
P WT/  for power function = q
q
1
2 61 5 i(. )
P FOOD =+ qq 34 1 ii ()Malaria Journal 2009, 8:304 http://www.malariajournal.com/content/8/1/304
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F is the unknown oral bioavailability), apparent volume
of distribution of the central compartment for AS (V2/F),
apparent clearance for DHA from the central compart-
ment (CLM/F), apparent central volume of distribution
for DHA (V3/F), inter-compartmental clearance for DHA
(Q/F), and apparent peripheral volume of distribution for
DHA (V4/F). Inter-individual variability (IIV) was esti-
mated for all parameters but Q/F and V4/F, since the avail-
able data would not support the inclusion of the two
terms. Fixing the variance of the random effects for Q/F
and V4/F to zero had little influence on the OFV, and was
essential for the model to minimize successfully and to
calculate the covariance matrix of the estimates. The pop-
ulation estimates of apparent clearance (CL/F) and vol-
ume of distribution (V2/F) for AS were 1190 L/h with
36.2% inter-individual variability (IIV) and 1210 L with
57.4% IIV, respectively. For DHA, the population esti-
mates of apparent clearance (CLM/F) and central volume
of distribution (V3/F) were 93.7 L/h with 28% IIV and
97.1 L with 30% IIV, respectively. The population esti-
mates of apparent inter-compartmental clearance (Q/F)
and peripheral volume of distribution (V4/F) for DHA
were 5.74 L/h and 18.5 L, respectively.
Food intake (FOOD) and total body weight (WT) were
found to be significant covariates on Ka and CLM/F,
respectively, in the following relationships:
The typical value of Ka for subjects taken the test drug
without food is 3.85 h-1. When the drug was taken with
high fat and high caloric meal, Ka of AS was reduced by
84%. The inclusion of food intake as a covariate in the
final model reduced the IIV of Ka from 135% to 112%,
indicating that this covariate accounted for 31% of the
variability on Ka. The apparent clearance of DHA, CLM/F
was correlated with total body weight, in which a unit
change in the weight would result in 1.9 unit change in
CLM/F in the same direction. With the incorporation of
weight in the final model, the IIV of CLM/F was reduced
from 31.4% to 28%, thus accounting for 20% of the vari-
ability.
Goodness-of-fit plots for AS and DHA indicated a reason-
able fit of the model to the data (Figure 2 and Figure 3).
Final estimates of the parameters are shown in Table 2.
The parameters were well estimated in general, with per-
cent relative standard error ranged from 2.3% to 36%.
Parameter related to absorption showed the most inter-
individual variability, with IIV for Ka was estimated to be
112% even after the incorporation of food intake as a cov-
ariate. Residual variability was higher for AS observations
than DHA observations.
Model evaluation
78% of the 500 non-parametric bootstrap runs converged
successfully. The parameter estimates and 95% confi-
dence interval for the parameters were calculated from the
converged runs and are presented in Table 2. The parame-
ter distributions were generally symmetrical. All the esti-
Ka FOOD  where FOOD  if fasted and FOOD  i =− = = 38 5 1 08 4 0 1 .( . ) , ii f f fed
CLM/F WT =+ − 93 7 1 9 61 5 .. ( . ) i
Schematic representation of the final structural model Figure 1
Schematic representation of the final structural model.
CMT 2: 
AS,
Central
V2
CMT 3: 
DHA,
Central
V3
Ka CL/F CLM/F
CMT 4: 
DHA,
Peripheral
V4
Q/F
CMT 1:
F*D
CMT: Compartment
F: Oral bioavailability
D: AS dose
Ka: Absorption rate constant
CL: AS clearance
V2: Central volume of distribution for AS
CLM: DHA clearance
V3: Central volume of distribution for DHA
Q: Inter-compartmental clearance
V4: Peripheral volume of distribution for DHAMalaria Journal 2009, 8:304 http://www.malariajournal.com/content/8/1/304
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mates obtained from the final model were comparable to
the bootstrap estimates and were contained within the
95% bootstrap confidence intervals. Figure 4 shows the
results of the visual predictive check for AS and DHA.
Overall, the final model adequately described the
observed concentrations. About 11.6% and 9.8% of the
AS and DHA observations were not contained within the
90% prediction interval. The condition number of the
final model was 24, indicating that the model was stable.
Discussion
In the current analysis, a novel parent-metabolite model
to describe the population pharmacokinetics of AS and
DHA in healthy subjects was developed. This is the first
population pharmacokinetic analysis of AS and DHA con-
Goodness-of-fit plots of artesunate (AS) for the final model Figure 2
Goodness-of-fit plots of artesunate (AS) for the final model. The solid lines in the upper left and right panels are lines 
of identity. The broken lines are smoothing lines.Malaria Journal 2009, 8:304 http://www.malariajournal.com/content/8/1/304
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ducted using data derived from a large number of healthy
subjects following oral administration of AS. The model
developed was stable and was able to predict AS and DHA
data arising from single- and multiple-dosing of oral AS
equally well.
AS was rapidly absorbed into the systemic circulation,
with an absorption half-life of 10.8 minutes estimated in
this analysis. The conversion of AS to DHA was very rapid
and the concentration of DHA was measurable as early as
20 minutes post-dose for all subjects. The sensitivity of the
assay used in this study enabled the measurement of AS
concentrations up to eight hours post-dose and the meas-
urement of DHA concentrations up to 12 hours post-dose,
in 65% and 95% out of the total 1416 available samples,
respectively. Therefore, we were able to characterize the
distribution of lipophilic DHA to the peripheral tissue.
The pharmacokinetic parameter estimates obtained using
a non-linear mixed-effects modelling approach employed
in this analysis are comparable with those obtained using
non-compartmental analysis (unpublished data).
Goodness-of-fit plots of dihyroartemisinin (DHA) for the final model Figure 3
Goodness-of-fit plots of dihyroartemisinin (DHA) for the final model. The solid lines in the upper left and right panels 
are lines of identity. The broken lines are smoothing lines.Malaria Journal 2009, 8:304 http://www.malariajournal.com/content/8/1/304
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Table 2: A summary of the results obtained from the final model and the bootstrap analysis.
Parameter Estimate %RSE Bootstrap estimate (95% CI)
CL/F (L/h) 1190 4.20 1176 (1060 -- 1280)
V2/F (L) 1210 5.77 1199 (1020 -- 1370)
Ka (h-1) 3.85 3.61 4.16 (2.66 -- 6.67)
CLM/F (L/h) 93.7 3.30 92.6 (86.5 -- 99.1)
V3/F (L) 97.1 4.85 96.5 (86.7 -- 107)
Q/F (L/h) 5.74 12.8 5.69 (3.72 -- 7.53)
V4/F (L) 18.5 10.6 18.7 (14.1 -- 23.2)
θFOOD-Ka -0.84 2.32 -0.836 (-0.915 -- -0.733)
θWT-CLM/F 1.90 16.3 1.78 (0.993 -- 2.58)
IIV (Variances and % CV)
IIV-CL/F 0.131 (36.2) 17.8 0.130 (0.0824 -- 0.176)
IIV-V2/F 0.330 (57.4) 20.9 0.347 (0.201 -- 0.497)
IIV-Ka 1.26 (112) 15.4 1.32 (0.751 -- 2.00)
IIV-CLM/F 0.0786 (28.0) 22.5 0.0740 (0.0411 -- 0.118)
IIV-V3/F 0.0901 (30.0) 36.0 0.0776 (0.0001 -- 0.151)
RV (%CV)
AS 37.5 9.73 37.5 (31.0 -- 45.2)
DHA 28.2 11.2 27.7 (21.6 -- 34.8)
RSE, relative standard error; CL/F, apparent clearance for AS; F, unknown bioavailability; V2/F, apparent volume of distribution of the central 
compartment for AS; Ka, absorption rate constant for AS, CLM/F, apparent clearance for DHA from the central compartment; V3/F, apparent 
central volume of distribution for DHA; Q/F, inter-compartmental clearance for DHA; V4/F, apparent peripheral volume of distribution for DHA; 
θFOOD-Ka, parameter for the covariate food intake on Ka; θWT-CLM/F, parameter for the covariate weight on CLM/F; CV, coefficient of variation; IIV, 
inter-individual variability; RV, residual variability; AS, artesunate; DHA, dihydroartemisinin.
Visual predictive check of the final model for artesunate (AS) and dihydroartemisinin (DHA) observations Figure 4
Visual predictive check of the final model for artesunate (AS) and dihydroartemisinin (DHA) observations. The 
open circles represent the observed concentrations, solid lines represent the 90% prediction interval obtained from the simu-
lations, and the dashed line represents the 50th percentile of the simulations.
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The pharmacokinetics of AS and DHA following orally
administered AS in healthy subjects have been previously
reported in different settings [23-26]. However, AS phar-
macokinetics was not described in the reports by Benakis
et al [23] and Na-Bangchang et al [26]. Navaratnam et al
[24] compared the pharmacokinetics of AS and DHA after
administration of oral and rectal AS in 12 healthy male
Malaysian volunteers using non-compartmental
approach. Following a single oral dose of 200 mg AS, the
mean area under the plasma concentration-time curve
(AUC) to time infinity for AS was reported to be 119 ng.h/
mL, corresponding to a CL/F of 1680 L/h. A lower CL/F for
AS (1190 L/h) was reported in the current analysis using
data from a much larger sample size. The bioanalytical
method used to measure AS plasma concentrations was
also more sensitive (limit of quantification = 1 ng/mL) in
current analysis. Teja-Isavadharm and colleagues [25]
studied the single-dose pharmacokinetics of AS following
the administration of 100 mg of oral AS in six healthy sub-
jects and six patients with uncomplicated falciparum
malaria. In their study, the range of apparent clearance
and apparent volume of distribution in healthy subjects
were 4.69-29 L/h/kg and 4.2-49.6 L/kg for AS, 1.66-3.26
L/h/kg and 1.99-4.45 L/kg for DHA, respectively. The
weight normalized apparent clearance and apparent vol-
ume of distribution obtained in this analysis were 19.3 L/
h/kg and 19.7 L/kg for AS, 1.52 L/h/kg and 1.88 L/kg for
DHA, respectively. The estimates obtained in this present
analysis are within the similar magnitude compared to
their findings.
Several other studies have described the pharmacokinetics
of DHA following the administration of oral AS in malar-
ial patients [27-29]. Newton et al studied the disposition
of DHA in 19 adult patients with acute uncomplicated fal-
ciparum malaria who were treated with 2 mg/kg of oral AS
[29]. DHA data was modelled using an open one-com-
partmental model with first order absorption and elimi-
nation assuming complete conversion of AS to DHA. The
reported CL/F and V/F values were 73.1 L/h and 70.5 L,
respectively. In another study, the pharmacokinetic char-
acteristics of DHA were described in 26 malarial patients
who received 100 mg of oral AS, using non-compartmen-
tal analysis [28]. The reported AUC and t1/2 of DHA were
4.53 μmols.h/L and 0.66 h, respectively. These values cor-
respond to a CL/F of 51.7 L/h and a V/F of 48.9 L. Simi-
larly, Bethell et al reported the AUC and t1/2 of DHA of
1286 ng.h/mL and 1 h, respectively, in 10 children with
moderately severe falciparum malaria who received 3 mg/
kg of oral AS [27]. These values correspond to a CL/F of
45.7 L/h and a V/F of 65.9 L. All these values for CL/F and
V/F of DHA were lower than the value reported in this
analysis. These differences could be resulted from the use
of different assays, the effect of disease state (malaria), dif-
ferences in the dose formulations, and/or the age-related
difference in DHA metabolism capacity.
Population pharmacokinetics of AS and/or DHA in
malaria patients have been described in four other papers
[14-17]. Karunajeewa et al [14] proposed a three-compart-
ment model (a rectal absorption compartment, a central
compartment for AS and a central compartment for DHA)
to describe the population pharmacokinetics of AS and
DHA simultaneously in paediatric patients following
administration of AS suppositories. Simpson et al [16]
modelled only the DHA data pooled from five Phase II
and III studies conducted in adult and paediatric malaria
patients. Both the weight-normalized CL/F and V/F for AS
obtained in our analysis are much larger than the ones
reported by Karunajeewa et al (5.9 L/h/kg and 2.1 L/kg,
respectively) [14]. The larger CL/F and V/F for AS seen in
our study might be attributed to the fact that the AS bioa-
vailability is reduced when oral AS is given compared to
rectal AS [24]. On the other hand, the weight-normalized
CL/F and V/F for DHA obtained in this study are smaller
than those reported by the two studies. Karunajeewa et al
reported values of 2.2 L/h/kg and 2.1 L/kg for the CL/F
and V/F of DHA [14]. The typical CL/F values of DHA
reported by Simpson et al were 3.17 L/h/kg for a male and
2.03 L/h/kg for a female. For an adult weighted 70 kg, the
typical value for V/F of DHA was 6.34 L/kg [16]. This find-
ing is also consistent with the observations that the AUC
for DHA following oral administration of AS was higher
than that following rectal AS [24,30], suggesting that the
bioavailability of DHA was increased when oral AS was
given.
McGready et al [15] characterized the population pharma-
cokinetics of DHA in pregnant women with acute uncom-
plicated falciparum malaria following a three-day dosing
of oral AS (4 mg/kg/day) and atovaquone plus proguanil.
However, the pharmacokinetics of AS was not evaluated
because AS was detectable only in about 6.5% of the total
available samples. The pharmacokinetic parameter esti-
mates for DHA were therefore derived using AS dose in
DHA equivalents. The CL/F of DHA was reported to be
1.77 L/h/kg, which is similar in our analysis. However, the
estimate for DHA apparent volume of distribution in
healthy Korean subjects obtained in this analysis is about
60% lower compared to the pregnant Karen patients in
their study (4.63 L/kg). The larger volume of distribution
seen in their study might be attributed to the physiologi-
cal changes during pregnancy and the effect of the disease
state.
Stepniewska et al conducted a population pharmacoki-
netic study of AS in African children with acute malaria
from six months to five years old [17]. The subjects
received either the fixed dose combination of AS and
amodiaquine or the separate tablets of both drugs. The
DHA data was modelled using nonlinear mixed-effects
approach. The weight normalized CL/F of DHA reported
in their study was 0.636 L/h/kg, which was almost 60%Malaria Journal 2009, 8:304 http://www.malariajournal.com/content/8/1/304
Page 11 of 13
(page number not for citation purposes)
lower than the value analysis in healthy adults. The dis-
crepancy could be related to the developmental changes
of metabolizing enzymes that take place in the young chil-
dren. It has been demonstrated that the glucuronidation
of DHA was catalyzed by UDP-glucuronosyltransferases
(UGTs), in particular UGT1A9 and UGT2B7 [21]. The
capacity of these metabolizing enzymes in young children
could be much less than the full capacity in adults [31]
and therefore resulted in lower CL/F of DHA. In a review
on developmental patterns of UGT system, de Wildt et al
suggested that the use of per-kg model for clearance is ade-
quate to address developmental changes in young chil-
dren and may lead the underestimation of clearance by up
to 200% in chilren under 3.4 kg of body weight [31]. The
reported weight-normalized V/F of DHA by Stepniewska
et al was 2.285 L/kg [17], which was quite similar to the
value obtained in this analysis.
In the present analysis, food intake was found to signifi-
cantly delay the absorption of AS. When AS dose was
administered after the intake of high-fat and high-caloric
meal, the population absorption half-life of AS increased
from 10.8 minutes to 67.5 minutes. However, the extent
of absorption was not altered significantly. Body weight
affected CLM/F significantly and therefore was included as
a covariate in the final model. The average CLM/F for a
healthy subject with 61.5 kg of body weight was estimated
to be 93.8 L/h. A unit deviation in body weight would
result in 1.9 unit deviation in the CLM/F from the popu-
lation estimate. None of the other covariates tested was
significant determinants of the variability seen. Co-
administration of PYR did not affect any of the pharma-
cokinetic parameters of AS and DHA.
Remarkable time-dependent pharmacokinetics of ARN
has been observed in both healthy subjects and in malaria
patients after single or repeated oral and rectal administra-
tion of ARN dose [32-35]. Auto-induction of CYP2B6 and
CYP2C19 was proposed to be the main mechanism caus-
ing the decline of plasma ARN concentrations [36-38]. A
semi-physiological pharmacokinetic model taking into
account the autoinduction phenomenon has been devel-
oped for ARN in healthy subjects [39]. Conflicting obser-
vations have been reported concerning the autoinduction
phenomenon after the administration of AS dose. In their
unconvincing report, Khanh et al [40] observed a decline
in DHA concentrations in 6 malaria patients following
repeated AS dosing. However, the decline in either AS or
DHA concentration was not observed in two other studies
[41,42]. In this analysis, the type of dosing was tested in
the covariate analysis to investigate any differences in the
pharmacokinetics of AS and DHA following the adminis-
tration of single- and multiple-dose of AS. None of the AS
and DHA pharmacokinetic parameters was affected by the
type of AS dosing received at a significance level of 0.05.
Visual predictive check plots in Figure 4 shows similar dis-
tributions for AS and DHA observations following single-
or multiple-dose of AS, indicating no sign of decline in AS
and DHA concentrations after three repeated daily AS dos-
ing. The model described the AS and DHA observations
equally well regardless the type of dosing received by the
healthy subjects. In addition, the mean AS/DHA AUC0-8
ratios were similar after single and multiple doses (0.10
and 0.11, respectively). This provides evidence that there
is little or no induction of the metabolic enzymes
involved in the metabolism of AS following once daily
dosing over three days.
Conclusions
A descriptive, robust and predictive parent-metabolite
model has been developed using population approach to
characterize the pharmacokinetics of AS and DHA simul-
taneously in healthy subjects following oral administra-
tion of AS. In addition, presence of food and weight were
found to impact the absorption and disposition of AS and
DHA. The pharmacokinetic parameter estimates obtained
in this analysis will also serve as a comparison for future
works involving the characterization of population phar-
macokinetics of AS and DHA following oral AS in malaria
patients.
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